the aid library

LIST OPTIONS

Filter

5872

The short-term effects of the implementation of the "Treat All" guidelines on ART service delivery costs in Namibia

Schutte, C.; Forsythe, S.; Fedes Mdala, J.; et al. (2020) CC2

PLoS ONE 15(1): e0228135. The introduction of “Treat All” (TA) has been promoted to increase the effectiveness of HIV/AIDS treatment by having patients initiate antiretroviral therapy at an earlier stage of their illness. The impact of introducing TA on the unit cost of treatment has been less ... more

External Link (119)

WASH Technical Paper: Tanzania - Country WASH M&E Roadmap

United Nations International Children's Emergency Fund UNICEF (2022) C_UNICEF

Tanzania WASH sector stakeholders collaborated between March and May 2022 to develop this Country WASH M&E Roadmap. The initial vision, outcomes and activities outlined in the Roadmap were established during a workshop, held on 2–3 March 2022, and further refined during a second workshop, held on ... more

Download (82)

View PDF (79)

Manual de transporte, almacenamiento y manejo de pruebas de diagnóstico rápido de la malaria en instalaciones de almacenamiento centrales y periféricas

Organización Panamericana de la Salud (2011) C_WHO

Este manual ofrece directrices prácticas para el manejo adecuado de las pruebas de diagnóstico rápido (PDR) de la malaria, destinadas al personal que trabaja en almacenes centrales, regionales y periféricos del sistema de salud. Su propósito principal es garantizar la integridad y eficacia de e... more

Download (504)

View PDF (723)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (1022)

View PDF (2168)

Core components of infection prevention and control programmes in health care

World Health Organization (2011)

Download (317)

View PDF (996)

Climate & Biodiversity

Expertise France (2021) C2

Expertise on #24 – Climate & Biodiversity - Expertise France

Download (346)

View PDF (552)

Planetary Health Report Card

International Medical School Initiative (2022) C2

The Planetary Health Report Card is a student-driven, metric-based initiative to inspire planetary health and sustainable healthcare education engagement in medical schools. In addition to inspiring expansion of medical school curricula, we hope to inspire medical schools to expand research efforts,... more

Download (814)

View PDF (933)

Resource needs for the Kenya Health Sector Strategic and Investment plan: Analysis Using the One Health Tool

USAID, Health Policy Project (2015) C1

Download (278)

View PDF (419)

What you need to know about HIV and COVID-19 in the context of human mobility

ONUSIDA; Response for Venezuelans (R4V) (2020) C2

COVID-19 is a disease caused by a new strain of coronavirus, a new coronavirus associated with the severe acute respiratory syndrome (SARS) viruses family and some coronaviruses associated with common cold. There is still no evidence that persons living with HIV have a higher risk of contracting CO... more

Download (2401)

View PDF (1822)

Cuidados pós-natais para mães e recémnascidos

OMS; USAID; CHIP; Maternal and Child Survival Program (2016) C_WHO

Destaques das diretrizes de 2013 da Organização Mundial da Saúde

Download (278)

View PDF (713)

Addressing Human Rights as Key to the COVID-19 Response

World Health Organization WHO (2020) C1

This document brings to attention key health and human rights considerations with regards to COVID-19 pandemic. It highlights the importance of integrating a human rights based approach in response to COVID-19. It provides key considerations in relation to addressing stigma and discrimination, preve... more

Download (461)

View PDF (559)

Kenya National Oral Health Policy 2022-2030

World Health Organisation (WHO) (2022) C_WHO

Oral health is defined as the absence of disease and a status that ensures optimal functioning of the mouth and its tissues in a manner preserving the highest level of function and self-esteem. Oral health enables an individual to eat, speak and socialise having no active disease, discomfort or disc... more

Download (377)

View PDF (655)

Die Umsetzung der globalen 2030 - Agenda für nachhaltige Entwicklung inklusiv gestalten

VENRO Verband Entwicklungspolitik und nachhaltige Entwicklung (2016) CC

In diesem gemeinsamen Forderungspapier formulieren der Deutsche Behindertenrat (DBR) und der Verband Entwicklungspolitik und Humanitäre Hilfe (VENRO)1 Anforderungen an die Fortschreibung der Nationalen Nachhaltigkeitsstrategie im Hinblick auf die Inklusion von Menschen mit Behinderungen

Download (298)

View PDF (486)

Food Safety in the time of COVID-19

Food and Agriculture Organization of the United Nations (2020) CC

Presently, there is no evidence that the virus responsible for the current COVID-19 pandemic is carried by domestic food-producing animals, such as chickens, ducks, other poultry, pigs, cattle, camels, horses, sheep, goats, rabbits, guinea pigs or fish. While live animals can be a source of pathogen... more

Download (223)

View PDF (233)

Information and criteria for prioritizing diagnostic tests for SARS-CoV-2 in order to address the procurement needs of health systems

OPS (2020) C_WHO

This document provides brief information answering common questions regarding COVID-19 diagnostic tests and how to prioritize them to the patients most in need.

External Link

COVID-19 Bangladesh situation reports

World Health Organization (WHO), Regional Office for South-East Asia (2022) C_WHO

Download (829)

View PDF (2199)

Garantizar el acceso a los servicios de la salud. Guía operativa para la protección de refugiados y las soluciones en áreas urbanas

La agencia de la ONU para los refugiados UNHCR ACNUR (2011)

Esta guía operativa se basa en las mejores prácticas y ejemplos ilustrativos de ciudades y pueblos donde la Agencia de Refugiados de la ONU (ACNUR) trabaja actualmente con refugiados en zonas urbanas. El papel del ACNUR en el ámbito de la salud pública es más complejo y menos definido en contex... more

Download (288)

View PDF (509)

Precisión diagnóstica de pruebas de detección de antígenos para SARS-Cov-2

Ministerio de Salud, Peru (2021) CC

La presente publicación describe la evidencia científica disponible sobre la precisión diagnóstica de las pruebas rápidas de detección de antígenos para SARS-COV-2. El conocimiento de las pruebas diagnósticas para el coronavirus del síndrome respiratorio agudo grave 2 (SARS-COV-2) sigue evo... more

Download (237)

View PDF (390)

Utilidad de Cloroquina e Hidroxicloroquina frente a COVID-19: Profilaxis y tratamiento

Ministerio de Salud, Peru (2021) CC

La presente publicación describe un resumen de la evidencia científica disponible sobre el uso de Cloroquina e hidroxicloroquina, así como su profilaxis y tratamiento para COVID-19. Esta publicación pertenece al compendio Publicaciones Minsa sobre COVID-19

Download (223)

View PDF (383)

Uso complementario de las pruebas moleculares y pruebas de detección de anticuerpos para el diagnóstico de COVID-19

Ministerio de Salud, Peru (2021) CC

La presente publicación describe la evidencia científica disponible sobre la utilidad del uso complementario de pruebas moleculares y de detección de anticuerpos para mejorar el diagnóstico de sospechosos de COVID-19. La utilización complementaria de ambas pruebas podría mejorar la identificac... more